E-Science Station

Lots of interesting abstracts and cases were submitted for TCTAP & AP VALVES 2020 Virtual. Below are accepted ones after thoroughly reviewed by our official reviewers. Don¡¯t miss the opportunity to explore your knowledge and interact with authors as well as virtual participants by sharing your opinion!

* The E-Science Station is well-optimized for PC.
We highly recommend you use a desktop computer or laptop to browse E-posters.

ABS20191112_0001
Valvular Intervention: Aortic
Initial experience with repositionable J-Valve for severe aortic regurgitation: a single-center experience
Lulu Liu1, Yingqiang Guo1
West China Hospital, China1
Background:
This study aimedto evaluate the clinical outcomes of treating high-riskpatients presenting with severe aortic regurgitation (AR) using transcatheteraortic valve replacement (TAVR).
Methods:
High-risk patients with symptomatic severe AR or AS undergo transapical implantation of the J-Valve¢ç prosthesis (JieCheng Medical Technology Co., Ltd., Suzhou, China) at our institution from March 2014 to July 2019 were enrolled consecutively. Clinical and echocardiographic outcomes were assessed at baseline, post-procedure, and30 days.
Results:
A total of 290 patients were included, 161 patients in the AR group and 129 patients in the AS group. Compared with patients in AS group pre-operatively, the gender, incidences of hypertension and diabetes, larger ascending aorta, left ventricular end-diastolic diameter (LVEDD), rate of the bicuspid valve and CT scan annulus, significantly different£¨P<0.05£©. AR group had larger valve size and better hemodynamic data than patients in the AS group (p < 0.05). Early post-operative data showed significantly higher new postoperative pacemaker implantation (PPMI) rate in patients in the AR group. The mean peak gradient and peak velocity was significantly higher in the AS group. Consistent with the preoperative data, LVEDD was larger in the AR group and LVEF was lower in the AR group (p < 0.05).
Conclusion:
Our registry data indicated that high-risk patients with AR have a comparable prognosis compared to a contemporary consecutive cohort of patients with AS. For those patients with severe AR or AS, using J-valve transcatheter heart valve (THV) TAVR is a valuable therapeutic option.
like off